Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1376 - 1400 of 1554 in total
This drug is classified as a reversible inhibitor of monoamine oxidase A enzyme (also known as a RIMA drug). It was developed and is currently used as an antidepressant in Russia. Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug. Pirlindole is a...
Experimental
Matched Salts name: … Pirlindole lactate
GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of Interleukin 15 (IL-15).
Investigational
Matched Description: … variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form
Investigational
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
Matched Description: … DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) …
Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. The origin plant, also known as the European white or silver birch, grows mainly in the northern hemisphere. This oil is usually obtained by using both hydrodistillation and micro-distillation and it...
Nutraceutical
A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.
Investigational
Nutraceutical
Matched Description: … A non-essential amino acid occurring in natural form as the L-isomer. …
Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.
Investigational
Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).
Investigational
Mersalyl is the sodium salt form of mersalyl acid, a mercurial diuretic. It is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577]. The sodium salt of a mercury-containing derivative of salicylamide, was formerly...
Experimental
Matched Description: … Mersalyl is the sodium salt form of mersalyl acid, a mercurial diuretic. …
The oral polio vaccine (OPV) is a live attenuated vaccine containing a mixture of one or more strains of poliovirus serotypes. Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that...
Investigational
Matched Description: … The polio vaccine can be either administered in the inactivated form or the oral form, although both ... series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are …
CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia.
Investigational
Investigational
Iron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3. It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.
Experimental
Matched Description: … It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, …
GS-441524 is an adenosine nucleotide analog antiviral, similar to remdesivir.[A203057,L13239] This molecule was patented in 2009. In vitro studies of GS-441524 have determined it has a higher EC50 than remdesivir against a number of viruses, meaning GS-441524 is less potent.[A203057,A203057] GS-441524 continues to be studied in the treatment of Feline...
Experimental
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. …
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
Matched Description: … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. …
TH-302 is a novel cancer therapeutic specifically activated under the low oxygen or "hypoxic" conditions typical of solid tumor cancer cells. TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide. TH-302 has been shown, in...
Investigational
CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Investigational
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
Investigational
Matched Description: … Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene …
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form
Displaying drugs 1376 - 1400 of 1554 in total